Recent data gleaned from a successful Phase III study of Selexipag sent stock prices up fifteen percent for the pharmaceutical company Actelion. As an efficacious next generation treatment for pulmonary arterial hypertension, also known as PAH, Selexipag has been forecasted by pharmaceutical analysts to become the next blockbuster drug. The advent of Selexipag as an[…]
Selexipag Set Up To Be Next Blockbuster PAH Treatment
Anti-Hypertensive, Drug Research & Development API Tags: PAHpulmonary arterial hypertension Jun 27, 2014
FDA Approves Macitentan for Pulmonary Arterial Hypertension
Cardiovascular Agent, Drug Research & Development API Tags: PAHpulmonary arterial hypertension Oct 24, 2013
On October 19, 2013 the FDA approved Macitentan for the treatment of pulmonary arterial hypertension, also known as PAH. As the first oral drug approved as a potential reduction for patient hospitalizations, Macitentan is also being touted to delay disease progression in patients with PAH. Actelion markets the brand name of Macitentan, coined Opsumit, is[…]
Exercise is Possible for Patients Suffering from PAH with Ambrisentan
Patent Expiration 2014, Respiratory Tract Agent Tags: GileadPAHpulmonary arterial hypertension Aug 01, 2012
Patients suffering from debilitating pulmonary arterial hypertension, or PAH, find extensive relief when treated with ambrisentan. Also known as the brand name Letairis, marketed by Gilead, ambrisentan is effectual at preventing the thickening of the blood vessels, particularly those in the heart and lungs. Ambrisentan, CAS number 177036-94-1, treats the high blood pressure in the[…]
Treprostinil Alleviates Pulmonary Hypertension Symptoms
Antithrombotic, Cardiovascular Agent, Drug Research & Development API, Prostaglandin Tags: hypertensionPAHprostaglandin Oct 18, 2011
Patients with pulmonary hypertension can look at Treprostinil and breathe a sigh of relief. For years, this type of hypertension has been managed by a limited choice of treatment options such as oxygen, vasodilators and prostaglandins. These two treatment options are used to “open up” the arteries which results in reduced pressure in the blood[…]
